Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.

被引：7
|
作者：
Tannir, Nizar M.
Signoretti, Sabina
Choueiri, Toni K.
McDermott, David F.
Motzer, Robert J.
George, Saby
Powles, Thomas
Donskov, Frede
Tykodi, Scott S.
Pal, Sumanta K.
Gupta, Saurabh
Lee, Chung-Wei
McHenry, M. Brent
Rini, Brian I.
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[5] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Roswell Pk Canc Inst, Buffalo, NY USA
[8] Queen Mary Univ London, Barts Canc Ctr, London, England
[9] Aarhus Univ Hosp, Aarhus, Denmark
[10] Univ Washington, Seattle, WA 98195 USA
[11] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[12] City Hope Natl Med Ctr, Duarte, CA USA
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.352
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
352
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
    Rini, B. I.
    Tannir, N. M.
    Escudier, B.
    McDermott, D. F.
    Grimm, M-O.
    Porta, C.
    Powles, T.
    Kollmannsberger, C. K.
    Gurney, H. P.
    Tykodi, S. S.
    Harrison, M.
    Heng, D. Y. C.
    Gruenwald, V.
    Choueiri, T. K.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    George, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
    Mantia, Charlene M.
    Jegede, Opeyemi A.
    Plimack, Elizabeth R.
    Powles, Thomas
    Motzer, Robert J.
    Tannir, Nizar M.
    Lee, Chung-Han
    Tomita, Yoshihiko
    Voss, Martin H.
    Choueiri, Toni K.
    Rini, Brian, I
    Hammers, Hans J.
    Escudier, Bernard
    Albiges, Laurence
    Rosenblatt, Lisa
    Atkins, Michael B.
    Regan, Meredith M.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 11
  • [23] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310
  • [24] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (11): : E518 - E518
  • [25] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
  • [26] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2019, 20 (10): : E559 - E559
  • [27] Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Plimack, Elizabeth R.
    McDermott, David F.
    Barthelemy, Philippe
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Gurney, Howard
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Escudier, Bernard
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Characterization of the benefit-risk profile of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced renal cell carcinoma (aRCC; CheckMate 214).
    Tannir, Nizar M.
    Hammers, Hans J.
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Mekan, Sabeen
    McHenry, M. Brent
    Kollmannsberger, Christian K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
    Grimm, Marc-Oliver
    Mcdermott, David F.
    Choueiri, Toni K.
    Motzer, Robert J.
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Rodriguez-Cid, Jeronimo
    Ishii, Yuko
    Mchenry, Brent
    Rini, Brian I.
    Tannir, Nizar M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 70 - 71
  • [30] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
    Burotto, Mauricio
    Powles, Thomas
    Escudier, Bernard
    Apolo, Andrea B.
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    George, Saby
    Scheffold, Christian
    Wang, Peter
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345